Dr. Wei Liu is a leading researcher and clinician specializing in geriatric cardiovascular medicine. He serves at both the Guangdong Provincial Geriatrics Institute, Guangdong Provincial People’s Hospital, and Shenzhen Baoan People’s Hospital. His research focuses on the molecular mechanisms underlying myocardial injury, cardiac fibrosis, and post-infarction remodeling, with emphasis on non-coding RNAs, RNA modifications, and inflammatory signaling pathways. Dr. Liu has published extensively in high-impact journals and plays a key role in advancing translational cardiology in aging populations.
🎓Education
-
Wei Liu has received comprehensive medical and research training in cardiovascular and geriatric medicine. While the specific institutions and degrees are not listed in the publication data, his position as a corresponding author affiliated with prestigious institutes such as Guangdong Provincial People’s Hospital and Shenzhen Baoan People’s Hospital indicates advanced medical and research education, likely including an MD or PhD in cardiovascular medicine, immunology, or a related biomedical field. His research maturity suggests postdoctoral training or equivalent experience in molecular cardiology or cardiovascular immunopathology.
👨🏫 Experience
-
Dr. Wei Liu currently serves in dual capacities within major Chinese medical institutions. He is a senior physician and researcher at the Department of Geriatric Cardiovascular Division, Guangdong Provincial Geriatrics Institute, Guangdong Provincial People’s Hospital, under the Guangdong Academy of Medical Sciences in Guangzhou. Additionally, he holds a position in the Department of Geriatric Medicine at Shenzhen Baoan People’s Hospital in Shenzhen. These roles reflect his leadership in clinical cardiology and translational research, especially focusing on aging populations and chronic cardiac conditions. His work integrates clinical care, molecular biology, and cardiovascular pathology.
🤝 Awards and Recognition
-
Dr. Liu’s role as a corresponding author in internationally peer-reviewed journals such as Biochimica et Biophysica Acta – Molecular Basis of Disease, Molecular Immunology, and Current Molecular Pharmacology indicates significant recognition within the cardiovascular research community. His multiple first and corresponding author publications in 2024 and 2025 imply active leadership in funded projects and recognition by research institutions, potentially including provincial or national medical research grants and academic honors.
💡Skills and Certifications
-
Dr. Liu possesses a multidisciplinary skill set combining clinical geriatric cardiology, molecular pharmacology, and immunopathology. His expertise includes in vivo cardiac modeling, myocardial infarction studies, regulatory RNA biology, inflammation signaling, and translational pharmacotherapy. He is proficient in experimental techniques involving gene expression regulation, immune cell signaling, and therapeutic intervention evaluations. His collaborative publications suggest strong skills in interdisciplinary research, experimental design, and scientific writing.
🔬 Research Focus
-
Dr. Liu’s research centers on the molecular mechanisms of cardiovascular disease, particularly myocardial fibrosis, cardiac hypertrophy, and myocardial injury related to inflammation and autoimmune responses. He investigates post-infarction remodeling processes, with emphasis on non-coding RNAs such as tRNA-derived fragments (tsRNAs), RNA modifications like ac4C and m5C, and associated regulatory proteins such as NAT10 and Alyref. His studies also explore cardioprotective pharmacological agents like artemisinin and ivabradine and their effects on signaling pathways including TGF-β1/Smad, ERK1/2, p38 MAPK, and JAK2/STAT3. This positions him at the forefront of translational cardiovascular research in China.
🌎Conclusion
-
Dr. Wei Liu exemplifies the qualities celebrated by the Research for Women Researcher Award—scientific excellence, clinical impact, and leadership in a critical area of healthcare. Her prolific research, academic leadership, and commitment to translational medicine make her a standout candidate. Recognizing her achievements through this award would not only honor her individual contributions but also inspire broader representation and advancement of women in medical science.
📖Publications
-
Title: tRNA-derived small RNA (tsr007330) regulates myocardial fibrosis after myocardial infarction through NAT10-mediated ac4C acetylation of EGR3 mRNA
Author: Hao Y, Li B, Yin F, Liu W*
Journal: Biochimica et Biophysica Acta – Molecular Basis of Disease, 2024
-
Title: IFITM3 mediates inflammation induced myocardial injury through JAK2/STAT3 signaling pathway
Author: Xiong C, Li B, Song R, Ma Z, Huber SA, Liu W*
Journal: Molecular Immunology, 2024
-
Title: Artemisinin attenuates isoproterenol-induced cardiac hypertrophy via the ERK1/2 and p38 MAPK signaling pathways
Author: Song RX, Xiong CM, Bai JC, Bai ZZ, Liu W*
Journal: Current Molecular Pharmacology, 2024
-
Title: Ivabradine alleviates experimental autoimmune myocarditis-mediated myocardial injury
Author: Zhu M, Lu J, Li X, An Y, Li B, Liu W*
Journal: International Heart Journal, 2024
-
Title: The m5C reader Alyref is involved in the regulation of cardiac remodeling after myocardial infarction through the synthesis of extracellular matrix proteins in cardiac fibroblasts
Author: Hao Y, Li B, Tian WD, Yin F, Liu W*
Journal: Biochimica et Biophysica Acta – Molecular Basis of Disease, 2025